Flupirtine Tablets: Clinical Information
Flupirtine is a non-opioid centrally acting analgesic with muscle relaxant properties that was used for moderate pain management, but has been largely withdrawn from markets due to significant hepatotoxicity concerns discovered after decades of use.
Critical Safety Warning
Hepatotoxicity is the primary concern with flupirtine, occurring in approximately 31% of patients receiving the drug for ≥6 weeks 1. This unexpected and frequent liver toxicity was discovered in 2012 during a clinical trial that had to be prematurely discontinued when major elevations of liver enzymes (>3 times upper normal limit) were detected in multiple patients 1. This finding is particularly concerning given that flupirtine had been marketed for approximately 30 years before this serious adverse effect was fully recognized.
Mechanism of Action
Flupirtine functions as a selective neuronal potassium channel opener (SNEPCO), the first drug in this pharmacological class 2. It works by:
- Facilitating M-current generation through opening of neuronal Kv7 potassium channels
- Producing indirect NMDA receptor antagonism via potassium channel activation
- Inhibiting exaggerated neuronal action potential generation
- Controlling neuronal hyperexcitability associated with chronic pain, migraine, and neurogenic pain 2
Indications
Based on available evidence, flupirtine was used for:
Acute Pain:
- Moderate pain from surgery, traumatic injury, dental procedures 3
- Headache/migraine 3
- Abdominal spasms 3
Chronic Pain:
- Musculoskeletal pain 3, 2
- Neuralgiform pain 3
- Lower back pain 2
- Dysmenorrhea 3
- Cancer pain (limited evidence) 3
Postcraniotomy Pain:
- Demonstrated 90.2% pain relief, comparable to diclofenac (90.5%) and superior to placebo (69.8%) 4
Dosing Recommendations
Standard Dosing
- Oral: 100-200 mg three to four times daily 3
- Rectal: 150 mg three to four times daily 3
- Maximum daily dose: 600 mg 3
- Modified-release formulation: 400 mg daily (100 mg fast-input + 300 mg slow-release portion) 5
Special Populations
Elderly Patients (≥60 years):
- Start with lower dose (½ tablet of modified-release formulation recommended) 5
- Systemic exposure increases by 30-50% in elderly patients compared to young adults 5
- EN1 (60-69 years): 1.30-fold increase in exposure
- EN2 (≥70 years): 1.50-fold increase in exposure 5
Severe Renal Dysfunction (CrCl ≤30 mL/min):
- Lower starting dose recommended (½ tablet) 5
- Systemic exposure increases by approximately 37% compared to normal renal function 5
- Neither age nor renal function was the predominant factor in pharmacokinetic variability, but individual patients may have relatively high exposure levels 5
Contraindications
While the provided evidence does not explicitly list contraindications from guidelines or drug labels, the research indicates:
- Absolute contraindication: Patients at risk for hepatotoxicity or with pre-existing liver disease (based on hepatotoxicity data)
- Relative contraindications: Convulsive disorders (mentioned in general NOAA context) 6
Adverse Effects Profile
Common Adverse Effects
The most frequently reported side effects include 3, 2:
- Drowsiness
- Dizziness
- Dry mouth
- Gastrointestinal complaints (heartburn, nausea)
- Fatigue
Serious Adverse Effects
Hepatotoxicity (31% incidence with ≥6 weeks use):
- Major liver enzyme elevations (>3× upper normal limit) 1
- This represents the most significant safety concern
Advantages Over Opioids
- No respiratory depression 3
- No cardiovascular depression 3
- No overt tolerance or physical dependence with prolonged administration 3
- Fewer central nervous system effects compared to opiates 3
Monitoring Requirements
Given the hepatotoxicity risk, mandatory monitoring should include:
- Baseline: Liver function tests (ALT, AST, bilirubin) before initiating therapy
- During treatment: Liver enzymes should be monitored at 2 weeks, 4 weeks, 6 weeks, and then monthly during continued use
- Discontinuation criteria: Immediately stop if liver enzymes exceed 3× upper normal limit
- Clinical monitoring: Watch for signs of liver dysfunction (jaundice, dark urine, right upper quadrant pain, unexplained fatigue)
Drug Interactions
Flupirtine demonstrates synergistic effects with morphine, increasing morphine's antinociceptive activity 4-fold when used in combination therapy 2. This suggests potential for opioid-sparing strategies, though hepatotoxicity concerns limit practical application.
Comparative Efficacy
Versus Other Analgesics:
- At least as effective as codeine, dihydrocodeine, and pentazocine 3
- Comparable to NSAIDs (suprofen, diclofenac, ketoprofen) 3
- Similar efficacy to dipyrone and paracetamol 3
- Equivalent to diclofenac for postcraniotomy pain 4
Versus Tramadol:
- Comparable analgesic properties for lower back pain 2
- Superior tolerability profile compared to tramadol 2
Clinical Considerations and Current Status
Critical Pitfall: The discovery of frequent hepatotoxicity after 30 years of clinical use 1 highlights that flupirtine's risk-benefit profile is unfavorable. Many European countries have withdrawn or severely restricted flupirtine due to these safety concerns.
If considering use (where still available):
- Reserve only for patients who have failed other analgesics
- Limit treatment duration to <6 weeks when possible
- Implement rigorous liver function monitoring
- Obtain informed consent regarding hepatotoxicity risk
- Consider alternative non-opioid analgesics first (NSAIDs, acetaminophen, gabapentinoids)
Pharmacokinetic Properties: